Coherus BioSciences, Inc. Stock

Equities

CHRS

US19249H1032

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
1.91 USD -4.98% Intraday chart for Coherus BioSciences, Inc. -11.98% -42.64%
Sales 2024 * 261M Sales 2025 * 358M Capitalization 231M
Net income 2024 * 40M Net income 2025 * -27M EV / Sales 2024 * 1.91 x
Net Debt 2024 * 268M Net Debt 2025 * 286M EV / Sales 2025 * 1.44 x
P/E ratio 2024 *
5.92 x
P/E ratio 2025 *
-8.4 x
Employees 249
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.96%
More Fundamentals * Assessed data
Dynamic Chart
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting CI
Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating MT
Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M MT
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Coherus Biosciences, Inc. Enters into a Senior Secured Term Loan Facility CI
Coherus BioSciences, Inc. Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan CI
Coherus BioSciences, Inc. announced that it has received $38.7 million in funding CI
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer CI
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting CI
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating MT
Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss MT
Transcript : Coherus BioSciences, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q4 Revenue $91.5M, vs. Street Est of $90.4M MT
Coherus BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
More news
1 day-4.98%
1 week-11.98%
Current month-2.55%
1 month-12.39%
3 months-25.97%
6 months-5.45%
Current year-42.64%
More quotes
1 week
1.90
Extreme 1.9
2.17
1 month
1.81
Extreme 1.81
2.32
Current year
1.81
Extreme 1.81
3.70
1 year
1.43
Extreme 1.4301
5.63
3 years
1.43
Extreme 1.4301
19.32
5 years
1.43
Extreme 1.4301
23.91
10 years
1.43
Extreme 1.4301
38.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 10-08-31
Director of Finance/CFO 46 21-02-28
Chief Tech/Sci/R&D Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 52 21-01-04
Director/Board Member 70 11-12-31
Director/Board Member 46 14-04-30
More insiders
Date Price Change Volume
24-05-24 1.91 -4.98% 1,432,097
24-05-23 2.01 -4.74% 1,287,418
24-05-22 2.11 +1.44% 1,089,038
24-05-21 2.08 0.00% 1,389,152
24-05-20 2.08 -1.89% 1,527,280

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.01 USD
Average target price
8.333 USD
Spread / Average Target
+314.59%
Consensus